Research and Development Department , VISSUM Corporation , E-03016 Alicante , Spain.
ACS Appl Mater Interfaces. 2019 Jan 16;11(2):1924-1931. doi: 10.1021/acsami.8b20222. Epub 2019 Jan 2.
Metal-organic frameworks (MOFs) have been evaluated as potential nanocarriers for intraocular incorporation of brimonidine tartrate to treat chronic glaucoma. Experimental results show that UiO-67 and MIL-100 (Fe) exhibit the highest loading capacity with values up to 50-60 wt %, whereas the performance is quite limited for MOFs with narrow cavities (below 0.8 nm, for example, UiO-66 and HKUST-1). The large loading capacity in UiO-67 is accompanied by an irreversible structural amorphization in aqueous and physiological media that promotes extended release kinetics above 12 days. Compared to the traditional drawbacks associated with the sudden release of the commercial drugs (e.g., ALPHAGAN), these results anticipate UiO-67 as a potential nanocarrier for drug delivery in intraocular therapeutics. These promising results are further supported by cytotoxicity tests using retinal photoreceptor cells (661W). Toxicity of these structures (including the metal nodes and organic ligands) for retinal cells is rather low for all samples evaluated, except for HKUST-1.
金属-有机骨架（MOFs）已被评估为将酒石酸溴莫尼定（一种治疗慢性青光眼的药物）纳入眼内的潜在纳米载体。实验结果表明，UiO-67 和 MIL-100（Fe）具有最高的负载能力，可达 50-60wt%，而对于空腔较窄的 MOFs（例如，小于 0.8nm 的 UiO-66 和 HKUST-1），其性能则相当有限。UiO-67 的高负载能力伴随着在水相和生理介质中的不可逆结构非晶化，从而促进了超过 12 天的延长释放动力学。与传统的商业药物（如 ALPHAGAN）突然释放相关的缺点相比，这些结果预示着 UiO-67 可能成为眼内治疗中药物输送的潜在纳米载体。这些有前途的结果进一步得到了使用视网膜光感受器细胞（661W）进行的细胞毒性测试的支持。对于所有评估的样品，除了 HKUST-1 外，这些结构（包括金属节点和有机配体）对视网膜细胞的毒性都相当低。
